Suzhou Zerun New Drug Research and Development

Suzhou Zerun New Drug Research and Development is a clinical-stage biopharmaceutical company based in Suzhou, China, and a subsidiary of Jiangsu Wuzhong Pharmaceutical Development. Established in 2019 through a collaboration with Zhejiang University, the company focuses on the discovery and development of innovative small molecule drugs and gene therapies. Its lead candidate, YS001, is a dual PI3K/mTOR inhibitor currently in Phase 1 clinical trials for the treatment of advanced malignant solid tumors, including breast and gastric cancers. The company leverages its R&D platform to target key signaling pathways in oncology, anti-viral, and immune regulation. Suzhou Zerun aims to address unmet medical needs by developing high-value innovative medicines with independent intellectual property.